TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: ETV Versus Shunt Surgery in Normal Pressure Hydrocephalus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with NPH~* Meet at least 2 of 3 Hakim and Adams diagnostic criterion for NPH (dementia, gait instability and urinary incontinence)~* Ventriculomegaly defined by CT or MRI, Evans' index \> 0.3~* Clinical improvement after 3 day trial of CSF drainage.~* MMSE\>24~* Informed consent from patient

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Shunt Arm (Type: None): Ventriculoperitoneal Shunt
- ETV arm (Type: None): Endoscopic Third Ventriculostomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 - 75~* elevated serum Insulin-like growth factor-1 (IGF-1) level above age- and sex-based normal values and failure of growth hormone(GH) suppression to \< 1.0 ng/ml after a 75 gm oral glucose tolerance test (OGTT) American Association of Clinical Endocrinolgists (AACE) Acromegaly Clinical Guidelines 2004~* visible pituitary adenoma (microadenoma or macroadenoma) on high quality pituitary MRI without and with gadolinium~* prior treatments for acromegaly with surgery, somatostatin analogs or pegvisomant are acceptable if these therapies have been discontinued for at least 3 months prior to study entry~Exclusion Criteria:~* Age \< 18 or \> 75 years~* acromegalic patients currently on a lanreotide or octreotide preparation or on pegvisomant~* patients who have received prior radiotherapy or radiosurgery~* patients with adenoma-related visual acuity or visual field deficit from optic nerve and/or chiasm compression or severe optic nerve/chiasm compression in the setting of normal visual fields and acuity~* patients with pituitary apoplexy defined as recent tumor hemorrhage and/or infarction on MRI with associated symptoms of new onset visual loss, diplopia and/or adrenal insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Somatuline Depot Subcutaneous (SC) (Type: EXPERIMENTAL): Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Calcineurin Activity in Renal Recipients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult renal transplant recipients~* treated by tacrolimus (Prograf or ADVAGRAF), corticoids, Cellcept,~Exclusion Criteria:~* patients with a high risk of bad compliance (toxicomania, severe psychiatric troubles)~* multiorgan transplant patients with mTOR inhibitors treatments~* HIV infected patients~* lack of consent for this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tacrolimus (Type: NO_INTERVENTION): Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mindfulness Rounds Initiative - A Short Mindfulness-Based Program for A Busy Workplace

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Employees on the Units~Exclusion Criteria:~- none

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mindfulness Rounds (Type: EXPERIMENTAL): Participants will be exposed to thrice weekly Mindfulness Rounds education on the Unit; participation in the actual sessions is voluntary.
- Control (Type: NO_INTERVENTION): No intervention will take place on this Unit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced colorectal carcinoma.~* Progression on prior oxaliplatin-containing regimen used in 1st line setting for mCRC or progression within 6 months of end of oxaliplatin-containing regimen in the adjuvant setting.~* Tumor tissue available at time of screening for molecular profiling.~* Adequate performance status.~* Adequate glucose control, bone marrow, kidney, liver, and heart function.~Exclusion Criteria:~* Participation in other studies involving investigational drug(s) (Phases 1-4) before the current study begins and/or during study participation.~* Prior irinotecan treatment.~* Prior radiation to the pelvis or abdomen in the metastatic or locally advanced setting.~* History of Gilbert's syndrome.~* Active brain metastases.~* Deep vein thrombosis in the preceding 2 months.~* History of interstitial lung disease.~* RAS (KRAS/NRAS) wild type mCRC not previously treated with an anti-EGFR containing regimen (unless contraindicated or not considered standard practice per clinical site or country guidelines).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): PF-05212384 plus FOLFIRI
- Arm B (Type: ACTIVE_COMPARATOR): Bevacizumab plus FOLFIRI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Project Healthy Eating in Children. A Study on the Health Effects of Fish Intake in Overweight Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* overweight (iso-BMI \> 25)~* 9-12 years~* healthy~Exclusion Criteria:~* diagnosed diseases such as diabetes, CVD, intestinal diseases, arthritis~* prescription medications affecting the metabolism of glucose, lipids or the immune system~* use of supplements containing long chain n-3 fatty acids~* high intake of fish~* food allergy

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Salmon Group (Type: None): Participants will eat 75 - 150 grams of salmon for dinner, three times a week for 12 weeks.
- Cod Group (Type: None): Participants will eat 75-150 grams of cod for dinner, three times a week for 12 weeks.
- Meat Group (Type: None): Participants will eat 75-150 grams of mixed meat for dinner, three times a week for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) Patient

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Those aged 18-75 diagnosed with probable or definite ALS.~Exclusion Criteria:~* Those with decision impairment will not be considered.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ALS (Type: None): Subjects having either definite or probable ALS by El Escorial Criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects with Duchenne muscular dystrophy who enrolled and completed study B5161002.~2. Signed and dated informed consent document (ICD) indicating that the subject's parent or legal guardian/caregiver has been informed of all pertinent aspects of the study.~3. Subjects and their legal guardians/caregivers who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.~4. Subject have;~   1. Adequate hepatic function on screening laboratory assessments~  2. GLDH less than 20 units/liter (2 x upper limit of normal \[ULN\])~  3. Iron content estimate on the liver MRI within the normal range.~Exclusion Criteria:~1. Unwilling or unable (eg, metal implants) to undergo examination with closed MRI.~2. All male subjects who are able to father children and are sexually active and at risk for impregnating a female partner, who are unwilling or unable to use a highly effective method of contraception. In addition, all sexually active male subjects who are unwilling or unable to prevent potential transfer of and exposure to drug through semen to their partners by using a condom consistently and correctly. .~3. Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or subjects who are related to Pfizer employees directly involved in the conduct of the study.~4. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation.~5. Participation in other studies involving investigational drug(s), with the exception of B5161002.~6. History of allergic or anaphylactic reaction to a therapeutic or diagnostic protein or additives of this investigational product.

- Gender: MALE
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- PF-06252616 (Type: EXPERIMENTAL): Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Controlled Trial to Evaluate CT Image Quality Lumentin® 44

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects of either gender at least 18 years at the time of signing the informed consent.~* Having a clinical indication for CT-examination of the abdomen~Exclusion Criteria:~* IV administration of iodine is contraindicated~* Known allergy to egg albumen~* Clinical suspicion, according to medical record, of fistula formation and/or leakage~* Referral indication of small bowel disease(s)~* Having known manifest thyrotoxicosis~* Having known phenylketonuria~* Having known Glucose-6-phosphatase deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lumentin® 44 (Type: EXPERIMENTAL): Contrast agent
- Diluted Omnipaque® (Type: ACTIVE_COMPARATOR): Contrast agent
- Movprep® (Type: ACTIVE_COMPARATOR): Contrast agent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: CPAP in Preeclampsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women 24-37 weeks pregnant~* Singleton pregnancy~* Primiparous and primigravid~* Maternal age 18-45 years~* Diagnosis of preeclampsia by their treating specialist (SBP\>140/90 and proteinuria\>300mg in 24 hours)~Exclusion Criteria:~* A previous diagnosis of hypertension, cardiac, respiratory or renal disease.~* Any regular cardiac or respiratory medications (PRIOR to pregnancy and diagnosis of preeclampsia)~* Current smokers

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): The control group will not be fitted with CPAP.
- CPAP group (Type: EXPERIMENTAL): The group will wear a CPAP device throughout the night. The mask fits comfortably over the nose and delivers a steady stream of air under slight pressure (auto-set).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment for Partial Lesions of the Fingers Flexor Tendons : Tangential Resection or Direct Suture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* wound dating less than 48 hours~* partial section from 50 % to 75 % of the flexor tendons (deep and/or superficial flexors, long flexor of the thumb) in zones 1, 2, 3, T1 and T2~* tendinous injuries on a single finger~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tangential resection (Type: EXPERIMENTAL): the tendon's injury is treated with a tangential resection
- Suture (Type: ACTIVE_COMPARATOR): The tendon's injury is sutured

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Supplemental Parenteral Nutrition in Pediatric Respiratory Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Admitted to study hospital pediatric intensive care unit (PICU),~2. One month to 16 years of age,~3. Exhibits Acute Hypoxemic Respiratory Failure as defined as: PaO2/FiO2 ≤ 300 or SpO2/FiO2 ≤ 260, No evidence of cardiac dysfunction, Mechanically ventilated,~4. Require artificial nutrition,~5. Anticipate placement of central venous line within 24 hours of admission~Exclusion Criteria:~1. Premature infants and neonates \< 37 weeks corrected gestational age,~2. Transfer patient on an established enteral or parenteral nutritional regimen,~3. Known allergy to lactulose or mannitol,~4. Pregnant,~5. Admit BMI \>30,~6. Thoracic trauma, abdominal trauma, and/or active intracranial bleeding,~7. Anuric renal failure, previous bowel surgery and/or short gut syndrome,~8. Cannot be enterally fed within 24 hours of admission according to the admitting physician,~9. On extracorporeal membrane oxygenation (ECMO),~10. Expected survival \<24 hours or limitations to aggressive ICU care (DNR),~11. Receiving active CPR when admitted to the PICU,~12. A pre-existing bronchopleural fistula,~13. Previously enrolled and randomized into this protocol,~14. Actively enrolled in another clinical trial which at the discretion of the PI would conflict with this study.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Early Parenteral Nutrition (Type: EXPERIMENTAL): Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
- Late Parenteral Nutrition (Type: ACTIVE_COMPARATOR): Patients receive supplemental parenteral nutrition 96 hours after enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine and Fentanyl Versus Midazolam and Remifentanil for Sedation in Patients Undergoing Ablation Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients listed for an ablation procedure for treatment of atrial fibrillation or flutter at TGH requiring sedation provided by an anesthetist~* Valid consent~Exclusion Criteria:~* Baseline HR \<40~* Baseline SBP \< 80mmHg~* Baseline SBP \> 180mmHg~* Second or third degree heart block unless pacemaker in situ~* Uncontrolled heart failure/severe LV dysfunction (Ejection fraction \< 40%)~* Severe hepatic dysfunction (Transaminases greater than 2 times the upper limit of normal)~* Renal dysfunction: estimated GFR \< 30ml/min, or requiring dialysis~* Allergy to any of the study drugs (dexmedetomidine, remifentanil, fentanyl, midazolam)~* Cognitive impairment precluding ability to tolerate sedation and comply with assessment methods~* Requirement for general anaesthetic for the procedure~* Pregnancy or breast feeding mothers~* Chronic use or addiction to opioids~* \< 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine Group (Type: EXPERIMENTAL): The study drug dexmedetomidine (PrecedexTM) is supplied as dexmedetomidine HCL 200mcg/vial (100mcg/ml). This will be added to 98 ml 0.9% NaCl to achieve a concentration of 2mcg/ml and infused at 0.2-1mcg/kg/hour from the start of the case. The infusion rate will be commenced at 1mcg/kg/hour in those less than or equal to 65 years of age, and at 0.7mcg/kg/hr in those greater than 65 years of age, and then titrated based on the intraoperative sedation scores (to achieve a Sedation and Agitation scale (SAS) score of less than or equal to 4) and cardiovascular parameters (within 30% of baseline).
- Remifentanil Group (Type: ACTIVE_COMPARATOR): Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1 Subjects who are undergoing endoscopic retrograde cholangiopancreatography (ERCP)~* Age \> 18 years~* Non-pregnant~* Non-prisoners~* Subjects who can sign informed consent~* Serum Creatinine \< 1.2 milligrams/deciliter (mg/dL)~* Subjects without renal failure (acute or chronic)~* Subjects without congestive heart failure (ejection fraction \< 40%)~* Subjects without cirrhosis of the liver~* Subjects without allergy to aspirin or non-steroidal anti-inflammatory drugs (NSAIDS)~* Subjects not on non-steroidal anti-inflammatory drugs NSAIDS prior to enrollment~Exclusion Criteria:~* Subjects who are not undergoing ERCP~* Age \< 18 years~* Pregnancy~* Prisoners~* Subjects lacking the capacity to consent for themselves~* Serum Creatinine \> 1.2 milligrams/deciliter (mg/dL)~* Subjects with renal failure (acute and chronic)~* Subjects with congestive heart failure (ejection fraction \< 40%)~* Subjects with cirrhosis of the liver~* Subjects with allergy to aspirin or non-steroidal anti-inflammatory drugs (NSAIDS)~* Subjects with gastrointestinal hemorrhage~* Subjects on chronic non-steroidal anti-inflammatory drugs NSAIDS~* Subjects with acute pancreatitis the day of their procedure (CITE 1-3)(APPENDIX 1)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A (NS+Placebo) (Type: PLACEBO_COMPARATOR): Normal Saline (intravenous during procedure) + Placebo (100mg suppository per rectum prior to procedure )
- B (NS+IND) (Type: ACTIVE_COMPARATOR): Normal Saline (intravenous during procedure) + Indomethacin (100mg suppository per rectum prior to procedure )
- C (LR+Placebo) (Type: ACTIVE_COMPARATOR): Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Placebo (100mg suppository per rectum prior to procedure)
- D (LR+IND) (Type: EXPERIMENTAL): Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Indomethacin (100mg suppository per rectum prior to procedure)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete